Calvin Sandra

SVP, CHIEF ACCOUNTING OFFICER

Calvin Sandra has filed 6 SEC Form 4 filings (20 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Sep 18, 2026.

On the most recent filing, Calvin Sandra is listed as SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc. Inside the rolling window, Calvin Sandra reported no open-market purchases and 6 open-market sales totaling $4.2M in TVTX. The largest disclosed transaction in the window is a sale of 67,115 TVTX shares on Nov 4, 2025, worth $2.4M.

Companies traded

Other insiders at TVTX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$4.2M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
TVTXSale$335KSep 18SEC ↗
TVTXSale$903KApr 16SEC ↗
TVTXSale$139KFeb 3SEC ↗
TVTXSale$296KDec 29SEC ↗
TVTXSale$105KDec 16SEC ↗
TVTXSale$2.4MNov 6SEC ↗
Showing 1–6 of 6
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Calvin Sandra made?

Calvin Sandra has filed 6 SEC Form 4 filings (20 transaction rows) across 1 company since 2025.

Which companies does Calvin Sandra trade?

Calvin Sandra has filed SEC Form 4 disclosures for 1 company, including TVTX.

When was Calvin Sandra's most recent SEC Form 4 filing?

Calvin Sandra's most recent SEC Form 4 filing on Tracefour is dated Sep 18, 2026.

What is Calvin Sandra's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Calvin Sandra is listed as SVP, CHIEF ACCOUNTING OFFICER.

What is Calvin Sandra's total buy and sell value in the current window?

Inside the rolling retention window, Calvin Sandra bought $0 and sold $4.2M based on SEC Form 4 filings.

What was Calvin Sandra's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 67,115 TVTX shares on 2025-11-04, worth $2.4M, per SEC Form 4 filings.